<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>neoadjuvant chemoimmunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/neoadjuvant-chemoimmunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 01 Oct 2025 03:11:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>neoadjuvant chemoimmunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neoadjuvant Chemoimmunotherapy Boosts Stage III Lung Cancer Outcomes</title>
		<link>https://bioengineer.org/neoadjuvant-chemoimmunotherapy-boosts-stage-iii-lung-cancer-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 01 Oct 2025 03:11:11 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[neoadjuvant chemoimmunotherapy]]></category>
		<category><![CDATA[pathological response rates]]></category>
		<category><![CDATA[PD-1 inhibitors (nivolumab]]></category>
		<category><![CDATA[pembrolizumab)]]></category>
		<category><![CDATA[stage III non-small cell lung cancer]]></category>
		<category><![CDATA[systematic review and meta-analysis]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neoadjuvant-chemoimmunotherapy-boosts-stage-iii-lung-cancer-outcomes/</guid>

					<description><![CDATA[In a groundbreaking advancement for the treatment of stage III locally advanced non-small cell lung cancer (NSCLC), recent research highlights the promising clinical benefits of neoadjuvant chemoimmunotherapy followed by surgical intervention. This innovative therapeutic approach combines chemotherapy with immunotherapy before surgery, aiming to optimize tumor response and improve patient outcomes in a cancer subtype traditionally [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">274155</post-id>	</item>
	</channel>
</rss>
